In (Newindiapress has reported) a major boost to image of Indian pharma major Ranbaxy Lab Ltd, the charges leveled by USFDA and department of Justice against Ranbaxy for submitting fabricated data and supplying substandard generics in US market is likely to be withdrawn by 3rd August, 2008.
Mr. Malvinder Singh, CEO of Ranbaxy, who announced that they have received a written communication and once Ranbnaxy complete filing all the information sought by the US FDA, the motion against Ranbnax will be withdrawn.
Earlier news by Ippharmadoc on this issue Here and Here
Mr. Malvinder Singh, CEO of Ranbaxy, who announced that they have received a written communication and once Ranbnaxy complete filing all the information sought by the US FDA, the motion against Ranbnax will be withdrawn.
Earlier news by Ippharmadoc on this issue Here and Here
No comments:
Post a Comment